Clinical practice guidelines for chronic hepatitis C virus infection
Authors:
Urbánek P. 1; Fraňková S. 2; Husa P. 3; Šperl J. 2; Plíšek S. 4; Rožnovský L. 5; Kümpel P. 6
Published in:
Gastroent Hepatol 2019; 73(2): 101-125
Category:
Hepatology: Best Practises
doi:
https://doi.org/10.14735/amgh2019101
Sources
1. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol 2018; 69 (2): 461–511. doi: 10.1016/j. jhep.2018.03.026.
2. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998; 47 (RR-19): 1–39.
3. Castéra L, Sebastiani G, Le Bail B et al. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol 2010; 52 (2): 191–198. doi: 10.1016/j.jhep.2009.11.008.
4. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017; 2 (3): 161–176. doi: 10.1016/S2468-1253 (16) 30181-9.
5. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol 2017; 66 (1): 153–194. 10.1016/j.jhep.2016.09.001.
6. Zeuzem S, Foster GR, Wang S et al. Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med 2018; 378 (4): 354–369. doi: 10.1056/NEJMoa1702417.
7. Forns X, Lee SS, Valdes J et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis 2017; 17 (10): 1062–1068. doi: 10.1016/S1473-3099 (17) 30496-6.
8. Afdhal N, Zeuzem S, Kwo P et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889–1898. doi: 10.1056/NEJMoa1402454.
9. Afdhal N, Reddy KR, Nelson DR et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370 (16): 1483–1493. doi: 10.1056/NEJMoa1316366.
10. Kowdley KV, Gordon SC, Reddy KR et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370 (20): 1879–1888. doi: 10.1056/NEJMoa1402355.
11. Naggie S, Cooper C, Saag M et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015; 373 (8): 705–713. doi: 10.1056/NEJMoa1501315.
12. Reddy KR, Bourlière M, Sulkowski M et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis. Hepatology 2015; 62 (1): 79–86. doi: 10.1002/hep.27826.
13. Wilson E, Kattakuzhy S, Kwo P et al. Real-world effectiveness of 8 vs 12 weeks of ledipasvir/sofosbuvir (LDV/SOF) in Blacks with HCV: a comparative analysis of clinical trials with real-world cohorts. Hepatology 2017; 66: 608A. [online]. Available from: http: //www.natap.org/2017/AASLD/AASLD_133.htm.
14. Kowdley KV, Sundaram V, Jeon CY et al. Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection. Hepatology 2017; 65 (4): 1094–1103. doi: 10.1002/hep.29005.
15. Buggisch P, Vermehren J, Mauss S et al. Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C. J Hepatol 2018; 68 (4): 663–671. doi: 10.1016/j.jhep.2017.11.009.
16. Zeuzem S, Ghalib R, Reddy KR et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 2015; 163 (1): 1–13. doi: 10.7326/M15-0785.
17. Rockstroh JK, Nelson M, Katlama C et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE COINFECTION): a non-randomised, open-label trial. Lancet HIV 2015; 2 (8): e319–e327. doi: 10.1016/S2352-3018 (15) 00114-9.
18. Kwo P, Gane EJ, Peng CY et al. Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection. Gastroenterology 2017; 152 (1): 164–175, e164. doi: 10.1053/j.gastro.2016.09.045.
19. Wei LJ, Zhdanov K, Burnevich E et al. Efficacy and safety of elbasvir/grazoprevir in treatment-naive patients with chronic HCV GT1, GT4 and GT6 infection (C-CORAL): a Phase III randomized multinational clinical trial. J Hepatol 2017; 66 (1): S529. doi: 10.1016/S0168-8278 (17) 31460-5.
20. Zeuzem S, Serfaty L, Vierling J et al. The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection. J Gastroenterol 2018; 53 (5): 679–688. doi: 10.1007/s00535-018-1429-3.
21. Abergel A, Hezode C, Asselah T et al. High efficacy and safety of grazoprevir and elbasvir for 8 weeks in treatment-naive, non-severe fibrosis HCV GT1b-infected patients: interim results of the STREAGER study. J Hepatol 2018; 68 (Suppl 1): S110. doi: 10.1016/S0168-8278 (18) 30437-9.
22. Ferenci P, Bernstein D, Lalezari J et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370: 1983–1992. doi: 10.1056/NEJMoa1402338.
23. Dore GJ, Conway B, Luo Y et al. Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: the MALACHITE-I/II trials. J Hepatol 2016; 64 (1): 19–28. doi: 10.1016/j.jhep.2015.08.015.
24. Wyles D, Saag M, Viani RM et al. TURQUOISE-I Part 1b: ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin for hepatitis C virus infection in HIV-1 coinfected patients on darunavir. J Infect Dis 2017; 215 (4): 599–605. doi: 10.1093/infdis/jiw597.
25. Welzel TM, Asselah T, Dumas EO et al. Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, Phase 3b trial. Lancet Gastroenterol Hepatol 2017; 2 (7): 494–500. doi: 10.1016/S2468-1253 (17) 30071-7.
26. Agarwal K, Gaeta BG, Lee SS et al. Long-term clinical outcomes in HCV genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin: first interim safety and efficacy results from TOPAZ-I. Hepatology 2016; 64: 427. [online]. Dostupné z: http: //www.natap.org/2016/AASLD/AASLD_54.htm.
27. Welzel TM, Isakov V, Trinh R et al. Efficacy and safety of ombitasvir, paritaprevir/ritonavir and dasabuvir without ribavirin in patients with HCV genotype 1b with or without compensated cirrhosis: pooled analysis across 5 clinical trials. J Hepatol 2016; 64 (2): S824. doi: https: //doi.org/10.1016/S0168-8278 (16) 01613-5.
28. Foster GR, Afdhal N, Roberts SK et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 2015; 373 (27): 2608–2617. doi: 10.1056/NEJMoa1512612.
29. Lawitz E, Mangia A, Wyles D et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368 (20): 1878–1887. doi: 10.1056/NEJMoa1214853.
30. Snopková S, Rozsypal H, Aster V et al. Doporučený postup péče o dospělé infikované HIV a postexpoziční profylaxe infekce HIV. [online]. Dostupné z: https: //www.infekce.cz/ DoporART16.htm.
Labels
Paediatric gastroenterology Gastroenterology and hepatology SurgeryArticle was published in
Gastroenterology and Hepatology
![Issue 2](https://www.prolekare.cz/media/cache/resolve/journal_issue/media/image_pdf/9399e593bc5ab0096d2e598434a4eb4e.jpeg)
2019 Issue 2
Most read in this issue
- A gastric Dieulafoy’s lesion
- Involvement of the gastrointestinal tract in amyloidosis: when to think about it and how to diagnose
- Ectopic pancreas as a cause of upper gastrointestinal bleeding
- Inflammatory bowel disease and male fertility